Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 11-Mar-24 5:19 PM View:  | Dibiase Mary Chief Operating Officer | X4 Pharmaceuticals, Inc (XFOR) | 11-Mar-24 | Sale | 15,409 | $0.88 | $13,590.70 | (5%) 307.16K to 291.75K | |
| 11-Mar-24 5:20 PM View: | Ragan Paula President and CEO Director | X4 Pharmaceuticals, Inc (XFOR) | 11-Mar-24 | Sale | 49,678 | $0.88 | $43,855.70 | (6%) 814.75K to 765.07K | |
| 11-Mar-24 5:20 PM View: | Taveras Arthur Chief Scientific Officer | X4 Pharmaceuticals, Inc (XFOR) | 11-Mar-24 | Sale | 14,235 | $0.88 | $12,552.40 | (6%) 248.54K to 234.3K | |
| 11-Mar-24 5:19 PM View: | Mostafa Adam S. Chief Financial Officer | X4 Pharmaceuticals, Inc (XFOR) | 11-Mar-24 | Sale | 52,500 | $0.88 | $46,347.00 | (100%) 52.5K to 0 | |
| 12-Feb-24 5:23 PM View: | Taveras Arthur Chief Scientific Officer | X4 Pharmaceuticals, Inc (XFOR) | 12-Feb-24 | Sale | 787 | $1.01 | $792.67 | (< 1%) 249.32K to 248.54K | |
| 12-Feb-24 5:03 PM View: | Mostafa Adam S. Chief Financial Officer | X4 Pharmaceuticals, Inc (XFOR) | 12-Feb-24 | Sale (Planned) | 27,721 | $1.01 | $27,973.30 | (35%) 80.22K to 52.5K | |
| 12-Feb-24 5:23 PM View: | Dibiase Mary Chief Operating Officer | X4 Pharmaceuticals, Inc (XFOR) | 12-Feb-24 | Sale | 3,683 | $1.01 | $3,708.78 | (1%) 310.84K to 307.16K | |
| 12-Feb-24 5:05 PM View: | Ragan Paula President and CEO Director | X4 Pharmaceuticals, Inc (XFOR) | 12-Feb-24 | Sale (Planned) | 21,695 | $1.01 | $21,892.40 | (3%) 836.44K to 814.75K | |
| 03-Nov-23 5:26 PM View: | Ragan Paula President and CEO Director | X4 Pharmaceuticals, Inc (XFOR) | 03-Nov-23 | Sale (Planned) | 39,906 | $0.90 | $35,915.40 | (5%) 876.35K to 836.44K | |
| 03-Nov-23 4:39 PM View: | Taveras Arthur Chief Scientific Officer | X4 Pharmaceuticals, Inc (XFOR) | 01-Nov-23 | Sale (Planned) | 67,695 | $0.73 | $49,417.40 | (21%) 317.02K to 249.32K | |
| 03-Nov-23 4:42 PM View: | Mostafa Adam S. Chief Financial Officer | X4 Pharmaceuticals, Inc (XFOR) | 01-Nov-23 | Sale (Planned) | 230,645 | $0.73 | $168,371.00 | (74%) 310.87K to 80.22K | |
| 03-Nov-23 5:26 PM View: | Ragan Paula President and CEO Director | X4 Pharmaceuticals, Inc (XFOR) | 01-Nov-23 | Sale (Planned) | 199,531 | $0.73 | $145,658.00 | (19%) 1.08M to 876.35K | |
| 03-Nov-23 4:39 PM View: | Baldry Mark Chief Commercial Officer | X4 Pharmaceuticals, Inc (XFOR) | 01-Nov-23 | Sale (Planned) | 10,257 | $0.73 | $7,487.61 | (29%) 34.95K to 24.69K | |
| 03-Nov-23 4:40 PM View: | Dibiase Mary Chief Operating Officer | X4 Pharmaceuticals, Inc (XFOR) | 01-Nov-23 | Sale (Planned) | 67,695 | $0.73 | $49,417.40 | (18%) 378.54K to 310.84K | |
| 02-Nov-23 4:55 PM View: | Dibiase Mary Chief Operating Officer | X4 Pharmaceuticals, Inc (XFOR) | 31-Oct-23 | Grant | 230,645 | -- | -- | 156% 147.89K to 378.54K | |
| 02-Nov-23 4:59 PM View: | Taveras Arthur Chief Scientific Officer | X4 Pharmaceuticals, Inc (XFOR) | 31-Oct-23 | Grant | 230,645 | -- | -- | 267% 86.37K to 317.02K | |
| 02-Nov-23 5:04 PM View: | Mostafa Adam S. Chief Financial Officer | X4 Pharmaceuticals, Inc (XFOR) | 31-Oct-23 | Grant | 230,645 | -- | -- | 288% 80.22K to 310.87K | |
| 02-Nov-23 4:58 PM View: | Ragan Paula President and CEO Director | X4 Pharmaceuticals, Inc (XFOR) | 31-Oct-23 | Grant | 532,081 | -- | -- | 98% 543.8K to 1.08M | |
| 02-Nov-23 5:00 PM View: | Baldry Mark Chief Commercial Officer | X4 Pharmaceuticals, Inc (XFOR) | 31-Oct-23 | Grant | 34,947 | -- | -- | 100% 0 to 34.95K | |
| 18-Oct-23 4:02 PM View: | Woods Keith Director | X4 Pharmaceuticals, Inc (XFOR) | 16-Oct-23 | Grant | 90,000 | -- | -- | 100% 0 to 90.0K | |
| 12-Sep-23 4:04 PM View: | Dibiase Mary Chief Operating Officer | X4 Pharmaceuticals, Inc (XFOR) | 08-Sep-23 | Sale (Planned) | 2,642 | $1.25 | $3,299.86 | (2%) 150.54K to 147.89K | |
| 22-Aug-23 4:09 PM View: | Wyzga Michael S Director | X4 Pharmaceuticals, Inc (XFOR) | 18-Aug-23 | Private Purchase | 25,000 | $1.20 | $29,875.00 | 48% 51.67K to 76.67K | |
| 11-Aug-23 7:26 PM View: | Stewart Murray Interim Chief Medical Officer Director | X4 Pharmaceuticals, Inc (XFOR) | 10-Aug-23 | Sale | 130,056 | $1.06 | $137,859.00 | (47%) 276.56K to 146.5K | |
| 11-Aug-23 7:26 PM View: | Stewart Murray Interim Chief Medical Officer Director | X4 Pharmaceuticals, Inc (XFOR) | 09-Aug-23 | Grant | 269,893 | -- | -- | 4048% 6.67K to 276.56K | |
| 05-Jul-23 4:05 PM View: | Dibiase Mary Chief Operating Officer | X4 Pharmaceuticals, Inc (XFOR) | 30-Jun-23 | Market Sale (Planned) | 464 | $1.89 | $876.96 | (< 1%) 151.0K to 150.54K | (12%) |
| 05-Jul-23 4:04 PM View: | Mostafa Adam S. Chief Financial Officer | X4 Pharmaceuticals, Inc (XFOR) | 30-Jun-23 | Market Sale (Planned) | 2,641 | $1.89 | $4,991.49 | (3%) 82.86K to 80.22K | (12%) |
| 26-Jun-23 4:15 PM View: | Dibiase Mary Chief Operating Officer | X4 Pharmaceuticals, Inc (XFOR) | 23-Jun-23 | Market Sale (Planned) | 857 | $1.93 | $1,654.01 | (< 1%) 151.86K to 151.0K | (10%) |
| 26-Jun-23 4:13 PM View: | Mostafa Adam S. Chief Financial Officer | X4 Pharmaceuticals, Inc (XFOR) | 23-Jun-23 | Market Sale (Planned) | 5,417 | $1.93 | $10,454.80 | (6%) 88.28K to 82.86K | (10%) |
| 26-Jun-23 4:11 PM View: | Ragan Paula President and CEO Director | X4 Pharmaceuticals, Inc (XFOR) | 23-Jun-23 | Market Sale (Planned) | 6,724 | $1.92 | $12,910.10 | (1%) 550.52K to 543.8K | (10%) |
| 16-Jun-23 4:15 PM View: | Ragan Paula President and CEO Director | X4 Pharmaceuticals, Inc (XFOR) | 15-Jun-23 | Market Sale | 6,724 | $2.23 | $14,994.50 | (1%) 557.25K to 550.52K | 5% |
| 16-Jun-23 4:17 PM View: | Mostafa Adam S. Chief Financial Officer | X4 Pharmaceuticals, Inc (XFOR) | 15-Jun-23 | Market Sale | 5,417 | $2.22 | $12,025.70 | (6%) 93.7K to 88.28K | 5% |
| 14-Jun-23 4:59 PM View: | Wyzga Michael S Director | X4 Pharmaceuticals, Inc (XFOR) | 13-Jun-23 | Grant | 45,000 | -- | -- | 675% 6.67K to 51.67K | |
| 14-Jun-23 5:05 PM View: | Bridger Gary Director | X4 Pharmaceuticals, Inc (XFOR) | 13-Jun-23 | Grant | 45,000 | -- | -- | 675% 6.67K to 51.67K | |
| 14-Jun-23 5:03 PM View: | McGirr David W J Director | X4 Pharmaceuticals, Inc (XFOR) | 13-Jun-23 | Grant | 45,000 | -- | -- | 675% 6.67K to 51.67K | |
| 14-Jun-23 4:51 PM View: | Lawton Alison Francis Director | X4 Pharmaceuticals, Inc (XFOR) | 13-Jun-23 | Grant | 45,000 | -- | -- | 675% 6.67K to 51.67K | |
| 14-Jun-23 5:10 PM View: | Aliski William Director | X4 Pharmaceuticals, Inc (XFOR) | 13-Jun-23 | Grant | 45,000 | -- | -- | 675% 6.67K to 51.67K | |
| 14-Jun-23 4:57 PM View: | de Craecker Francoise Director | X4 Pharmaceuticals, Inc (XFOR) | 13-Jun-23 | Grant | 45,000 | -- | -- | 675% 6.67K to 51.67K | |
| 31-May-23 5:05 PM View: | Ragan Paula President and CEO Director | X4 Pharmaceuticals, Inc (XFOR) | 31-May-23 | Market Sale | 6,292 | $1.95 | $12,269.40 | (1%) 563.54K to 557.25K | (9%) |
| 13-Mar-23 4:48 PM View: | Taveras Arthur Chief Scientific Officer | X4 Pharmaceuticals, Inc (XFOR) | 10-Mar-23 | Sale | 16,806 | $0.84 | $14,117.00 | (16%) 103.18K to 86.37K | |
| 13-Mar-23 4:50 PM View: | Mostafa Adam S. Chief Financial Officer | X4 Pharmaceuticals, Inc (XFOR) | 10-Mar-23 | Sale | 52,500 | $0.84 | $44,100.00 | (36%) 146.2K to 93.7K | |
| 13-Mar-23 4:46 PM View: | Ragan Paula President and CEO Director | X4 Pharmaceuticals, Inc (XFOR) | 10-Mar-23 | Sale | 49,678 | $0.84 | $41,729.50 | (8%) 613.22K to 563.54K | |
| 13-Mar-23 4:52 PM View: | Dibiase Mary Chief Operating Officer | X4 Pharmaceuticals, Inc (XFOR) | 10-Mar-23 | Sale | 18,192 | $0.84 | $15,281.30 | (11%) 170.91K to 152.71K | |
| 15-Feb-23 5:12 PM View: | Mostafa Adam S. Chief Financial Officer | X4 Pharmaceuticals, Inc (XFOR) | 13-Feb-23 | Sale | 27,721 | $0.93 | $25,780.50 | (16%) 173.92K to 146.2K | |
| 15-Feb-23 5:11 PM View: | Ragan Paula President and CEO Director | X4 Pharmaceuticals, Inc (XFOR) | 13-Feb-23 | Sale | 21,695 | $0.93 | $20,176.30 | (3%) 634.91K to 613.22K | |
| 15-Feb-23 5:13 PM View: | Dibiase Mary Chief Operating Officer | X4 Pharmaceuticals, Inc (XFOR) | 13-Feb-23 | Sale | 4,348 | $0.93 | $4,043.64 | (2%) 175.25K to 170.91K | |
| 15-Feb-23 5:13 PM View: | Taveras Arthur Chief Scientific Officer | X4 Pharmaceuticals, Inc (XFOR) | 13-Feb-23 | Sale | 928 | $0.93 | $863.04 | (< 1%) 104.11K to 103.18K | |
| 19-Aug-22 1:07 PM View: | Dibiase Mary Chief Operating Officer | X4 Pharmaceuticals, Inc (XFOR) | 17-Aug-22 | Sale (Planned) | 1,713 | -- | -- | (< 1%) 179.61K to 177.9K | |
| 19-Aug-22 1:08 PM View: | Meisner Derek M Chief Legal Officer | X4 Pharmaceuticals, Inc (XFOR) | 17-Aug-22 | Sale (Planned) | 8,334 | -- | -- | (5%) 153.49K to 145.16K | |
| 19-Aug-22 1:04 PM View: | Mostafa Adam S. Chief Financial Officer | X4 Pharmaceuticals, Inc (XFOR) | 17-Aug-22 | Sale (Planned) | 10,834 | -- | -- | (6%) 184.75K to 173.92K | |
| 19-Aug-22 1:05 PM View: | Ragan Paula President and CEO Director | X4 Pharmaceuticals, Inc (XFOR) | 17-Aug-22 | Sale (Planned) | 13,448 | -- | -- | (2%) 648.36K to 634.91K |
